Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?

Anti-EGFR therapy and antiangiogenic therapies are used alone or in combination with chemotherapies to improve survival in metastatic colorectal cancer. However, it is unknown whether pretreatment with antiangiogenic therapy could impact on the efficacy of anti-EGFR therapy. We selected one hundred...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Derangère, Valentin, Fumet, Jean David, Boidot, Romain, Bengrine, Leila, Limagne, Emeric, Chevriaux, Angélique, Vincent, Julie, Ladoire, Sylvain, Apetoh, Lionel, Rébé, Cédric, Ghiringhelli, François
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2016
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4891042/
https://ncbi.nlm.nih.gov/pubmed/26824184
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7008
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires